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Epothilone DThe MAP6 (microtubule-associated protein 6) KOmouse is a microtubule-deﬁcient model of schizophrenia that
exhibits severe behavioral disorders that are associated with synaptic plasticity anomalies. These defects are al-
leviated not only by neuroleptics, which are the gold standard molecules for the treatment of schizophrenia, but
also by Epothilone D (Epo D), which is a microtubule-stabilizing molecule. To compare the neuronal transport
between MAP6 KO and wild-type mice and to measure the effect of Epo D treatment on neuronal transport in
KO mice, MnCl2 was injected in the primary somatosensory cortex. Then, using manganese-enhanced magnetic
resonance imaging (MEMRI), we followed the propagation of Mn2+ through axonal tracts and brain regions that
are connected to the somatosensory cortex. In MAP6 KO mice, the measure of the MRI relative signal intensity
over 24 h revealed that the Mn2+ transport rate was affected with a stronger effect on long-range and polysyn-
aptic connections than in short-range andmonosynaptic tracts. The chronic treatment ofMAP6KOmicewith Epo
D strongly increased Mn2+ propagation within both mono- and polysynaptic connections. Our results clearly in-
dicate an in vivo deﬁcit in neuronal Mn2+ transport in KOMAP6mice, whichmight be due to both axonal trans-
port defects and synaptic transmission impairments. EpoD treatment alleviated the axonal transport defects, and
this improvement most likely contributes to the positive effect of Epo D on behavioral defects in KOMAP6 mice.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
The neurobiology of psychiatric disorders remains unclear; how-
ever, there is increasing evidence of white matter abnormalities
(Fitzsimmons et al., 2009; Palau-Baduell et al., 2012) together with re-
gional volumetric defects that are associated with a reduction in tract
size and with abnormal microstructures. Furthermore, anomalies in
neuronal transport that were initially reported in neurodegenerative
diseases, including Alzheimer's disease, Huntington's disease and
amyotrophic lateral sclerosis (ALS) (De Vos et al., 2007; Stokin et al.,
2005; Szebenyi et al., 2003), are now strongly suggested in psychiatricMEMRI, manganese-enhanced




. This is an open access article underdisorders (Costas et al., 2013; Friocourt et al., 2011; Taya et al., 2007;
Willemsen et al., 2012). In vitro, axonal transport is usually directly
measured using cultured neurons to analyze cargo trafﬁc. In vivo, neuro-
nal transport integrates not only axonal transport but also synaptic
transmission and tools to characterize neuronal transport in live ani-
mals and the effect of a pharmacological treatment on transport param-
eters are of great interest. In this respect, manganese-enhanced
magnetic resonance imaging (MEMRI) (Bertrand et al., 2013; Smith
et al., 2007), which relies on the use ofmanganese (Mn2+) as a contrast
agent, is an extremely powerful technique for characterizing neuronal
transport in animals. Similar to gadolinium, Mn2+ decreases T1 and T2
relaxation times. Mn2+ is able to enter neurons through voltage-
dependent calcium (Ca2+) channels (Narita et al., 1990), is transported
along axons and can cross synapses (Pautler, 2004; Pautler and
Koretsky, 2002; Pautler et al., 1998; Saleem et al., 2002). Thus, when lo-
cally injected,Mn2+ acts as an anterograde trans-synaptic tracer that al-
lows the track-tracing kinetic of speciﬁc neuronal tracts. This method
has been used to analyze several neuronal pathways, includingthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
134 A. Daoust et al. / NeuroImage 96 (2014) 133–142noradrenergic, corticocortical or corticothalamic tracts (Bearer et al.,
2009; Pautler and Koretsky, 2002; Pautler et al., 1998; Soria et al.,
2008; Tucciarone et al., 2009; Van der Linden et al., 2002; Yu et al.,
2005).
In this study, we evaluate in vivo neuronal transport in the MAP6/
STOP KO mouse, which is an animal model of a psychiatric disorder
where the microtubule-associated protein MAP6 has been deleted
(Andrieux et al., 2002). MAP6 KO mice exhibited neuroanatomical def-
icits, such as a reduction in brain volume (Powell et al., 2007), which is
associatedwith behavioral disorders that are associatedwith several al-
terations in many neurotransmission systems (Andrieux et al., 2002;
Bouvrais-Veret et al., 2007; Brenner et al., 2007; Brun et al., 2005;
Fournet et al., 2010). These behavioral and neurochemical alterations,
which recapitulate some of the clinical features of schizophrenia, have
been shown to be alleviated by chronic treatment with typical or atyp-
ical antipsychotics (Bégou et al., 2008; Delotterie et al., 2010). Interest-
ingly, microtubule-related drugs, such as Epo D (KOS-862) or NAP
(davunetide), ameliorated the cognitive behavior of MAP6 deﬁcient
mice (Andrieux et al., 2006; Fournet et al., 2012; Merenlender-
Wagner et al., 2010), which indicated that the pharmacologicalmodula-
tion of microtubule dynamics/stability might regulate integrated brain
functions. Moreover, synaptic deﬁcits in the brains of the MAP6 KO
mice, corresponding to a decrease of synaptic vesicle pools and the
impairment of synaptic plasticity, have been shown (Andrieux et al.,
2002). We hypothesized that MAP6 KOmicemight present a reduction
in neuronal transport that would be detectable by MEMRI.
Here, using MEMRI, we assayed neuronal transport within somato-
sensory cortex projections of MAP6 KO mice compared with wild-type
animals. We found that MAP6 KO mice exhibited an altered neuronal
transport capacity, which was associated with the alteration of some
white matter tracts. Interestingly, we showed that Epo D treatment
was able to alleviate the neuronal transport defects that were exhibited
by MAP6 KO mice.
Materials and methods
Mice and experiments
All experiments were performed on a C57Bl6/129SvPas-F1 genetic
background. The homogeneous inbred C57BL6/129SvPas-F1 mice
were obtained by crossing pure heterozygote 129SvPas MAP6 mice
with pure heterozygote C57BL6MAP6 mice. All experiments were con-
ducted on female wild type (WT) (n = 10) and MAP6 KO (n= 30) lit-
termate mice at 3–6 months of age, in compliance with the European
Community Council Directive of November 24, 1986 (86/609/EEC)
(permit number 81105 for A.D.; agreement of ethics committee n°004).
Two different experiments that were performed in this study are
summarized below.
In experiment 1 (related to Figs. 1, 2 and 3), Mn2+ transport was
assessed in vivo using MEMRI in WT mice (n = 10) and in MAP6 KO
mice (n=10), and then, themicewere killed. Postmortem, the somato-
sensory cortex pathway was traced using the monosynaptic tracer DiI
(n = 3 WT; n = 3 KO). Myelin tracts were labeled with gold chloride
(n = 5 WT; n = 5 KO). In experiment 2 (related to Fig. 4), KO MAP6
mice were treated with Epo D (n = 10) or with the vehicle solution
(n = 10). In both groups, Mn2+ transport was assessed using MEMRI
before and after treatment.
MEMRI
Surgery and tracer injection
Hydrated manganese chloride (100 mM, MnCl2–4H2O, M1787,
Sigma-Aldrich, St Louis, MO, USA) was dissolved in 10 mM Tris–HCl,
pH 7.3. The Mn2+ solution was ﬁltered through 0.2 μm membranes
before use. For Mn2+ administration, animals were sedated with an
intraperitoneal (ip) injection of xylazine (10 μL/g; 0.1% diluted in NaCl9/1000; Rompun®, Virbac, France). Five minutes later, anesthesia was
induced by an ip injection of ketamine (10 μL/g; 10 g/L diluted in NaCl
9/1000; Imalgène 1000®, Virbac, France). Animals were placed in a ste-
reotaxic frame. The coordinates were determined following the Paxinos
and Franklin atlas (Paxinos andWatson, 1998). A holewas drilled in the
skull, and through this hole, a 34 G silica cannula (Phymep, France) was
implanted into the primary somatosensory cortex (S1) (anterior–
posterior:−0.6 mm; lateral:−2.0 mm; and ventral:−0.7 mm). Sixty
nanoliters of Mn2+ solution were instilled at a rate of 8 nL/min via a
connected Hamilton syringe. Ten minutes after the end of the injection,
the cannula was retracted stepwise to avoid leakage of the tracer along
the injection track. After surgery, the skin was sutured, and animals re-
ceived a local anesthetic (bupivacaine, Vétoquinol, France) directly on
the wound. Animals also received a subcutaneous injection of an anti-
inﬂammatory (caprofen; 5 μg/g, Rimadyl®, Virbac, France) and antibi-
otics (sulfadoxine 20% and trimethoprim 4%; 0.125 μL/g, Borgal®,
Virbac, France). Throughout the entire surgical procedure, the rectal
temperature was maintained at 37 °C with a heating pad.In vivo MRI
MRI was performed 2, 6, 10 and 24 h after MnCl2 injection in a hori-
zontal 7T MRI system (Avance III, Bruker, Ettlingen, Germany) using a
surface/volume cross coil conﬁguration. Anesthetized animals (isoﬂurane
(IsoFlo, Axience, France); 5% for induction, maintenance under 2.5%)
were placed in a dedicated cradle, which was equipped with bite
and ear bars. T1-weighted images were obtained (MDEFT 3D, TR/TE =
4000/3.65ms, TI=1000ms, voxel size: 109 × 109×250 μm). The acqui-
sition durationwas 17min. The temperature and the breathing ratewere
monitored.
The MRI data were analyzed using software that was developed in
the Matlab environment (Mathworks, Natick, MA, USA). Five regions
of interest (ROI) were manually drawn in ipsi- and contralateral hemi-
spheres: internal capsule (ic), somatosensory cortex S1 (S1), anterior
(Ant. TH) and posterior (Post. TH) thalamus and the cerebral peduncle
(cp). The signal from the ipsilateral S1 ROI, which corresponded to the
injection site, was used as a reference to compensate for the variability
in the injected amount of Mn2+ solution. Therefore, the MEMRI signal
that was measured in each ROI was divided by the MEMRI signal that
was measured in the ipsilateral S1 ROI. The normalized MEMRI signal
is called the relative signal intensity (RSI) for the rest of themanuscript.Histology
After the ip administration of a lethal dose of sodium pentobarbital
(100 mg/kg; Dolethal, IPV, France), all experiment 1 animals were
transcardially perfused with a 4% PFA solution as described previously
(Raponi et al., 2007). The brains were removed from the skulls, stored
overnight in a 4% PFA solution at 4 °C and distributed into two groups
for two different histological procedures.Cortical tract tracing
A DiI crystal (1,1′-dioctadecyl-3,3,3′,3′-tetramethyl-indocarbocyanine
perchlorate, Sigma) was placed in the injection site that was used for the
Mn2+ solution. DiI is a lipid diffusing along axons throughout the plasma
membrane, from the cell body to the synapse. It does not cross synapses.
After threemonths of incubation at 37 °C in 4% PFA solution, coronal (n=
2 WT; n = 2 KO) and sagittal (n = 1 WT; n = 1 KO) sections (30 μm
thick) were obtained using a vibrating blade microtome (VT1000S, Leica
Biosystem, Nanterre, France). Sections were placed on glass slides, and
coverslips were mounted using ﬂuorescent mounting medium (Scytek,
Logan, UT, USA). Each section was digitized using a DMI6000 microscope
(Leica Biosystem, Nanterre, France), which was equipped with a 40× dry
objective and an EMCCD Quantum camera that was driven by the
Metamorph software (Roper Scientiﬁc, Every, France).
Fig. 1.Mono- and polysynaptic pathways of the somatosensory cortex, as revealed by DiI implantation and by MEMRI. (A) Schematic representation of major brain regions mono- (red)
and polysynaptically (black) connected to the ipsilateral somatosensory cortex S1 (injection site). (B) Chronogram of the experiments, related to this ﬁgure and to Fig. 2 (detailed in the
Materials and methods section). The MEMRI technique is composed of an intracerebral injection of Mn2+ into the cortex S1, following by four MRI acquisitions at 2, 6, 10 and 24 h after
Mn2+ injection. FollowingMEMRI, mice were ﬁxed with PFA, and DiI crystals were implanted in the same injection site as Mn2+. DiI ﬂuorescence signal was assayed after an incubation
period of threemonths in PFA ﬁxative solution. (C–D) DiI (C) andMEMRI (D) images (10 h) that correspond to the same brain of oneWTmouse. Three anatomic planes are represented:
anterior coronal (plane a), posterior coronal (plane b) and sagittal (plane c). For each technique, the imaging is shown (top), and the corresponding signal is diagrammed on an anatomical
plane (bottom). (E) High magniﬁcation of squared areas that are shown in DiI panels in C. Scale bar: 1 mm. In coronal planes (a and b) and in the sagittal plane c, bregma and lateral are
respectively indicated inmm.Abbreviations: Ant. TH: anterior thalamus; Cb: cerebellum; cc: corpus callosum; cp: cerebral peduncle; ic: internal capsule; IC: inferior colliculus; Pn: Pontine
nuclei; S1: primary somatosensory cortex; S2: secondary somatosensory cortex; Post. TH: posterior thalamus, LV: lateral ventricle, M: motor cortex and ec: external capsule.
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Fig. 2.MEMRI revealed a deﬁcit of neuronal transport in MAP6 KO mice. (A) MEMRI acquisitions were performed at 2, 6, 10 and 24 h post-Mn2+ injection. All regions of interest (ROIs)
were manually drawn on MEMRI images using their matched anatomic atlas plane as a reference. Diagrams represent matched anatomical planes with colored ROIs: internal capsule
(ic, green); anterior thalamus (Ant. TH, blue); cerebral peduncle (cp, khaki) and posterior thalamus (Post. TH, red). Two representative MEMRI images of a WT brain at 10 h post-
Mn2+ injection with ROIs (dotted red lines) were shown. Scale bar of MEMRI signal intensity is represented. (B) Representative graph of the relative signal intensity (RSI) evolution ac-
cording to time after theMn2+ injection in the ipsilateral internal capsule ofWT and KOmice. RSI values increased linearly over the time andwere signiﬁcantly reduced inMAP6 KOmice.
(C) Histograms of slope averages for ipsi- and contralateral ROIs. (D) Histograms of RSI averages for ipsi- and contralateral ROIs at 24 h afterMn2+ injection. n= 10WT; n=10MAP6 KO.
The values are the mean ± SEM. *p b 0.05; **p b 0.01. Abbreviations: Ant. TH: anterior thalamus; cp: cerebral peduncle; ic: internal capsule; Post. TH: posterior thalamus.
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Brains were placed in ascending concentrations of sucrose (10, 20
and 30% in PBS) until they sank, frozen in−40 °C isopentane and storedat −80 °C. Floating coronal sections (25 μm thick) were obtained
around the injection site (+/−3 mm) using a cryomicrotome (Microm
H560,MicromMicrotech, France). The sectionswere then stained using
Fig. 3. The internal capsule and the cerebral peduncle were reduced in MAP6 KO mice. (A) Representative brain sections in anterior and posterior planes are shown with their matched
coronal diagrams. After chloride gold and cresyl violet staining, the myelinated ﬁber tracts appeared in red, and cellular bodies appeared in blue. Note the size reduction of the internal
capsule (ic, green arrows) and of the cerebellar peduncle (cp, khaki arrows) in MAP6 KO mice. The reduction in these tracts was associated with a reduction in projection areas, such
as the thalamus (Ant. TH, blue arrows and Post. TH, red arrows). ROIs are indicated with dotted colored lines. (B) Table showing surface areas of brain regions and comparisons of
areas betweenWT and KOmice. n=5WT; n=5 KOMAP6. The values are themean± SEM (*p b 0.05; **p b 0.01; ***p b 0.001). Scale bar=1mm. Abbreviations: cp: cerebral peduncle;
cc: corpus callosum; ic: internal capsule; Ant. TH: anterior thalamus; Post. TH: posterior thalamus.
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sections were rinsed three times in PBS and incubated with 0.2% gold
chloride for 2 h at room temperature. To stop the reaction, sections
were incubated in 2.5% sodium thiosulfate, which was diluted in
distilled water, for 5 min. After three rinses in PBS, ﬂoating sections
were mounted on Superfrost Plus slides (Menzel-Gläser), and neurons
were counterstained with cresyl violet. Each section was digitized
(stereo microscope EZ4 HD, Leica Biosystem, Nanterre, France) and an-
alyzed using the ImageJ software. Four ROIs were drawn manually on
each hemisphere (in Ant. and Post. sections) using a mouse brain atlas
(Paxinos and Watson, 1998) as a reference (internal capsule, cerebral
peduncle and anterior and posterior thalamus), and their area was
determined.
Evaluation of the effect of Epo D
Epo D was provided by the Gesellschaft für Biotechnologische
Forschung (GBF) (Braunschweig, Germany). Epo D chronic treatment
was performed as previously described (Andrieux et al., 2006; Fournet
et al., 2012). Brieﬂy, one week after MEMRI was performed at 24 h
post-injection, mice received an intraperitoneal injection (ip) of either
1 mg/kg Epo D (200 μL/30 g body weight; n = 10) or vehicle only,
once a week for eight weeks. The drug was diluted in warm water
from a 50 mg/mL stock solution in dimethyl sulfoxide (DMSO). In con-
trol animals, vehicle injections consisted of 200 μL of corresponding
mixtures of DMSO alone in warm water. During the week following
the last ip administration, mice underwent a second MEMRI session,
which was performed 2, 6, 10 and 24 h after MnCl2 injection.
Statistical analysis
The results were expressed as the mean ± S.E.M. Unpaired t-tests,
which were performed using the Microsoft Excel software, were used toassess differences. Values were considered signiﬁcant when *p b 0.05,
**p b 0.001 and ***p b 0.0001. To evaluate whether the time after Mn2+
injection is a predictor of the RSI in MEMRI images, the p-value for
Pearson's correlation coefﬁcient (R2) was computed.
Results
Tracing of the somatosensory pathway
Reduced sensory gating appears to be among the core features of
schizophrenia (Patterson et al., 2008), and MAP6 KO mice exhibited
abnormal prepulse inhibition (PPI), which is indicative of abnormal
sensory-gating abilities (Fradley et al., 2005; Volle et al., 2013). Thus,
we thought to examine the somatosensory neuronal circuit, which is a
well-documented and characterized circuit (Leergaard et al., 2003;
von Bartheld et al., 1990). The main efferent projections of the somato-
sensory cortex (S1 cortex) circuit are composed of corticocortical,
corticopontine, corticothalamic and corticotectal projections through-
out four major tracts: the corpus callosum (cc), the internal capsule
(ic), the external capsule (ec) and the cerebral peduncle (cp) (Fig. 1A).
We traced the somatosensory pathway byMEMRI and classical DiI trac-
ing, which followed the time course that is illustrated in Fig. 1B. Because
DiI is a lipophilic neuronal tracer that freely diffuses in the plasmamem-
brane, Dil will allow the characterization of neuronal tracts and brain
projection areas that are monosynaptically connected to the injection
area. Three months after DiI implantation, the implantation site (so-
matosensory cortex 1, S1) and the neighboring motor cortex (M2) ex-
hibited a strong ﬂuorescence signal (Fig. 1C, plane a). As expected, DiI
primarily diffused to ipsilateral structures, such as the internal capsule
(ic), thalamic regions (Ant. TH, Post. TH), cerebral peduncle (cp) and
cortical areas S2 (Fig. 1C, planes a–c and Fig. 1E). In the contralateral
138 A. Daoust et al. / NeuroImage 96 (2014) 133–142side, only the S1 cortex, which was monosynaptically connected to the
ipsilateral S1 cortex (Leergaard et al., 2003), was visible (Fig. 1C, plane
a and Fig. 1E, panel 1). DiI appeared limited to short-range connections(5 to 10 mm); themonosynaptic connected brain stem regions, such as
the superior colliculus (SC) and pontine nuclei (Pn), were totally devoid
of ﬂuorescence signal (Fig. 1C, plane c).
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that Mn2+ transport was not restricted to monosynaptic and short-
range connections. Two hours after Mn2+ injection, the MEMRI signal
was hyperintense in the injection site (somatosensory cortex 1, S1)
and in some structures of the ipsilateral hemisphere, but not in the
hemisphere that was contralateral to the injection site (data not
shown). Six and ten hours after Mn2+ injection (Fig. 1D), the MEMRI
signal was extended to all ipsi- and contralateral structures that were
associated with the somatosensory pathways, such as the anterior and
posterior thalamus (Ant. TH, Post. TH), the corpus callosum (cc), the in-
ternal capsule (ic) and the cerebral peduncle (cp) (Fig. 1D, planes a–b).
In the ipsilateral hemisphere, a slightly enhanced signal was also ob-
served in the secondary somatosensory cortex (S2) and in the contralat-
eral S1 cortex (data not shown). The sagittal view showed that the
MEMRI signal was also enhanced in the brainstem, primarily in the infe-
rior colliculus (IC), pontinenuclei (Pn) and the cerebellum(Cb) (Fig. 1D,
plane c). Twenty-four hours afterMn2+ injection, theMEMRI signalwas
more diffuse than that observed at 10h; however, corticothalamic struc-
tures could still be readily depicted (data not shown).
However, in structures that were labeled by both Mn2+ and DiI,
the MEMRI signal was more diffuse than that of DiI. This signal was
particularly striking in the thalamus (Fig. 1C–D, planes a–b and Fig. 1E,
panel 3).
Distribution patterns of Mn2+ or of DiI within the somatosensory
structures of WT andMAP6 KOmice revealed no qualitative differences
(data not shown), which suggested that all analyzed structures of the
somatosensory pathway were properly connected in MAP6 KO mice.Manganese neuronal transport in MAP6 KO mice
The neuronal transport capacity of wild-type and MAP6 KO mice
was measured using MEMRI. Manganese relative signal intensities
(RSI) between WT and KO MAP6 animals were measured (Fig. 2A)
within equivalent tracts and brain regions that were monosynaptically
(ipsilateral side) or polysynaptically (contralateral side) connected to
S1 cortex injection site (Fig. 1A) at several time points (2, 6, 10 and
24h).Within the ipsilateral internal capsule, RSI value increases linearly
over time (ic; Fig. 2B and see Supplementary ﬁgure) in both WT (R2 =
0.9969; p = 1.6 × 10−3) and KOMAP6 (R2 = 0.9977; p = 1.2 × 10−3)
mice; however, the comparison of slope values, which were relative to
the speed of Mn2+ neuronal transport, was 33% lower in KO than in
WTmice (p= 0.011). The linear increase of RSI over timewas observed
for all ipsi- and contralateral brain areas that were analyzed (data not
shown). For all ipsi- and contralateral regions of interest (ROIs), we cal-
culated slope values forWT andKOmice (histograms, Fig. 2C). In ipsilat-
eral ROIs, slope values in MAP6 KOmice were 33% lower in the internal
capsule and 29% lower in the cerebral peduncle than in WT (Fig. 2C, ic
and cp, p = 0.01 and p= 0.009, respectively). Slope values in the ante-
rior and posterior thalamus, although reduced in MAP6 KO mice, were
not signiﬁcantly different (Fig. 2C, Ant. TH and Post. TH, p = 0.19
and p = 0.17, respectively). In contralateral ROIs, all slope values from
polysynaptic regions that were connected to S1 cortex were lower in
KO MAP6 mice, with a reduction of 39% for the internal capsule
(Fig. 2C, ic, p = 0.006), 45% for the anterior thalamus (Fig. 2C, Ant. TH,
p = 0.005), 43% for the cerebral peduncle (Fig. 2C, cp, p = 0.004) and
41% for the posterior thalamus (Fig. 2C, Post. TH, p = 0.009). Statistical
analysis showed that the neuronal transport rate of Mn2+ in KO miceFig. 4. EpoD improved the neuronal transport ofMn2+ in KOMAP6mice. (A) chronogram of th
two groups of KOmice at 24 h after Mn2+ injection. One week after the MEMRI, Epo D or vehic
treatment (AT), Mn2+ neuronal transportwas assessed byMEMRI sessions at 2, 6, 10 and 24 h p
mice before treatment (Epo D or vehicle). (C) Representative graph of the relative signal intens
of vehicle KO AT and Epo D KO ATmice. (D) Histograms of slope averages for ipsi- and contrala
Mn2+ injection. n=10vehicle KO; n=10 EpoDKO. The values are themean±SEM. *p b 0.05
ic: internal capsule; Post. TH: posterior thalamus.had a more pronounced effect on contra- than on ipsilateral ROIs
(−42% and−23%, respectively; p = 0.024).
RSI values, relative to the amount of accumulated manganese, that
were measured 24 h after Mn2+ injection were reported in Fig. 2D.
RSI values were lower in MAP6 KO mice and more affected in the con-
tralateral side of KO mice. In ipsilateral ROIs, RSI values in MAP6 KO
mice were lower by 21% in the internal capsule and by 21% in the
cerebral peduncle (Fig. 2D, ic and cp, p = 0.005 and p= 0.006, respec-
tively). RSI values in the anterior and posterior thalamus were not
signiﬁcantly different (Fig. 2D, Ant. TH and Post. TH, p = 0.065 and
p = 0.102, respectively). In contralateral ROIs, all RSI values were re-
duced by 24% in the internal capsule (Fig. 2C, ic, p = 0.012), 26% in
the anterior thalamus (Fig. 2D, Ant. TH, p = 0.035), 28% in the cerebral
peduncle (Fig. 2D, cp, p = 0.011) and 23% in the posterior thalamus
(Fig. 2D, Post. TH, p = 0.049). As observed for slope values, RSI reduc-
tions were more pronounced in contralateral than in ipsilateral ROIs
(−21% and−15%, respectively; p = 0.026).
These MEMRI results showed that MAP6 KO mice exhibit neuronal
transport deﬁcits that affect both ipsi- and contralateral sides, with a
more pronounced effect in the contralateral side that is possibly related
to long-range and polysynaptic connections.
Axonal tract size in KO MAP6 mice
Theneuronal transport deﬁcit thatwas observed usingMEMRI could
involve a reduction in the size of axonal tracts. Thus, we performed gold
staining of brain sections to assess the size of tracts and of some brain
areas. After chloride gold and cresyl violet staining, the myelinated
tracts appear in red, and cellular bodies appear in blue. The internal
capsule (ic) and the cerebral peduncle (cp) appeared much smaller
in KO MAP6 mice than in WT mice in both sides (Fig. 3A, ic and cp; ar-
rows). In MAP6 KO mice, there are signiﬁcant quantitative decreases
for the internal capsule (Fig. 3B, ipsi. ic,−51%, p = 1.6 × 10−4; contra,
−47%, p= 0.013) and for the cerebral peduncle (Fig. 3B, ipsi. cp,−27%,
p = 0.02; contra. cp,−27%, p = 0.01). In MAP6 KO mice, the surfaces
of the anterior and posterior thalamic structures were reduced in
the same range as a previously reported reduction (Powell et al.,
2007). In the MAP6 KO mouse brain, the anterior and the posterior
thalamus were reduced (Fig. 3B, ipsi. Ant. TH,−29%, p = 0.003; Post.
TH, −25%, p = 0.04; contra. Ant. TH, −28%, p = 0.006; Post. TH,
−28%, p = 0.006).
This gold staining reveals that KO MAP6 exhibited strong and equal
reductions in the size of internal capsule and of the cerebellar peduncle,
which affected both hemispheres. Thus, if the reduction in axonal tract
size can contribute to the abnormal neuronal transport in MAP6 KO,
as detected using MEMRI, then other mechanisms, such as a reduction
in the speed of axonal transport and/or abnormal synaptic transmission,
are most likely present and may explain the more pronounced defects
in the contra- compared with the ipsilateral side.
Effect of Epo D on neuronal transport in MAP6 KO mice
Epothilone D (Epo D) is a taxol-like microtubule stabilizing com-
pound that has been previously shown to improve behavioral and syn-
aptic deﬁcits ofMAP6KOmice (Andrieux et al., 2006). UsingMEMRI, we
assayed whether a chronic treatment with Epo D might improve the
neuronal transport deﬁcit that has been observed in MAP6 KO mice
(Fig. 4A). Before treatment (BT) with Epo D, manganese RSI valuese experiment. Oneweek before EpoD or vehicle treatment (BT), MEMRI was performed on
le was weekly injected into KOMAP6 mice for eight weeks. One week after the end of the
ost-Mn2+ injection. (B) Histograms of RSI values at 24 h afterMn2+ injection inMAP6 KO
ity (RSI) evolution according to time afterMn2+ injection in the ipsilateral internal capsule
teral ROIs. (E) Histograms of the RSI averages for ipsi- and contralateral ROIs at 24 h after
; **p b 0.01; ***p b 0.001. Abbreviations: Ant. TH: anterior thalamus; cp: cerebral peduncle;
140 A. Daoust et al. / NeuroImage 96 (2014) 133–142that were measured at 24 h were similar in all analyzed ROIs between
the vehicle (DMSO KO BT) and the Epo D (Epo D KO BT) animals
(Fig. 4B). After chronic treatment (AT) with Epo D (Epo D KO AT) or
DMSO (vehicle KO AT), the distribution pattern of Mn2+ between
both groups was qualitatively similar (data not shown).
The RSI values after treatment by either the Epo D or the vehicle
were thenmeasured. As illustrated in Fig. 4, panel C for the ipsilateral in-
ternal capsule (ic), RSI values increased linearly over time in both Epo
D-treated mice (Epo D KO AT; R2 = 0.9709, p = 0.015) and vehicle-
treated mice (vehicle KO AT; R2 = 0.9654; p = 0.017). However, strik-
ingly, after chronic Epo D treatment, the slope value was higher by 67%
(p=1.4 × 10−4), which indicated that Epo D improvedMn2+ neuronal
transport in KOmice rate in the ipsilateral internal capsule. Slope values
were then calculated for each ROI, and the results clearly indicated
that Epo D signiﬁcantly increased the neuronal transport rate in
almost all ipsi- and contralateral ROIs (Fig. 4D). In both ipsi- and contra-
lateral ROIs, the slope value increased by an average of 51% (p = 0.004
and p= 0.005, respectively). These results showed that Epo D stimulat-
ed Mn2+ transport in an equivalent manner in both ipsi- and contralat-
eral brain regions. To note, slope values of Epo D-treated KO mice
(Fig. 4C; y = 1.63) did not reach that of WT mice (Fig. 2B; y = 1.81).
The quantiﬁcation of RSI intensities in all ROIs was then performed
(Fig. 4E) and led to the same conclusions. In all ROIs at 24 h post-
injection, RSI values of Epo D-treated mice were higher than values for
vehicle-treated mice (Fig. 4E), with a similar increase of approximately
18% and 16% in ipsi- and contralateral ROIs, respectively (p= 0.006 and
p = 0.001, respectively).
Altogether, these results showed that Epo D treatment strongly
stimulates the neuronal transport of Mn2+.
Discussion
In this study, usingMEMRI in live animals, we showed thatMAP6KO
mice exhibit an altered neuronal transport capacity, which is associated
with a deﬁcit in some white matter tracts. MAP6 KO mice transported
lessMn2+ between the S1 cortex and projection areas than theWT con-
trol mice, particularly in contralateral structures. Mn2+ transport relies
on axonal transport and on synaptic activity, which includes neuro-
transmitter liberation and re-uptake. The transport ofMn2+ ismediated
by several mechanisms, which include the transport of intracellular
vesicles (Pautler, 2004) and mitochondria (Morello et al., 2008), the
stability of microtubules (Takeda et al., 1998), the viscosity of the cyto-
sol, the efﬁciency of microtubule motors (Bearer et al., 2007), the inten-
sity of the release and capture of synaptic vesicles (Drapeau and
Nachshen, 1984; Pastor et al., 2008) and the number of axons. The ab-
normal neuronal transport that was observed in MAP6 mice can be
the result of several abnormalities, such as reduced axonal tract size,
reducedmicrotubule stability and abnormal synaptic efﬁciency. Indeed,
we reported reductions in several tract sizes, which were associated
with a reduction in the thalamic regions inMAP6 KOmice. These reduc-
tions might affect both the speed of neuronal transport (relative to the
slope of RSI over time) and Mn2+ accumulation (relative to the RSI at
24 h post-injection). However, the reductions in axonal tracts do not
fully contribute to this defect because the tract reduction is similar in
both hemispheres, whereas the transport reduction is more severe in
the contralateral region. InMAP6 KO brains, a reduced number of gluta-
matergic synaptic vesicles have been reported (Andrieux et al., 2002).
This abnormality most likely is a crucial contributor to the neuronal
transport deﬁcit in the contralateral region, where synaptic transmis-
sion was required. Altogether, our results demonstrate that MEMRI
was sensitive enough to characterize, in vivo, alterations of neuronal
transport inMAP6 KOmice. Similar abnormalMn2+neuronal transport,
as measured by MEMRI, has been reported for other animal models of
psychiatric disorders and of neurodegenerative diseases, including
Alzheimer's-related mutant mice (Bearer et al., 2007, 2009; Bertrand
et al., 2013; Gallagher et al., 2012; Jouroukhin et al., 2013; Kim et al.,2011; Lutkenhoff et al., 2012; Sharp and Ross, 2012; Smith et al., 2007,
2010, 2011; Wang et al., 2012; Yu et al., 2011).
Epo D is a microtubule-stabilizing agent, which is related to taxol,
but that has good blood–brain barrier permeability; when intraperito-
neally injected, Epo D is retained in the brain (Brunden et al., 2010).
The chronic treatment of MAP6 KO mice with a low dose Epo D has
been shown to improve their cognitive behaviors and has been correlat-
edwith positive effects on synaptic vesicle number and synaptic plastic-
ity within the hippocampus (Andrieux et al., 2006; Fournet et al., 2012).
Here, we demonstrate that Epo D treatment strongly stimulates, in the
same range, the speed of neuronal transport in both ipsi- and contralat-
eral hemisphere sides. This improvement in neuronal transport might
also contribute to the positive action of Epo D on integrated functions
of MAP6 KO mice. The improvement of neuronal transport by Epo D
might involve the amelioration of axonal transport. Indeed, in tauopathy
models where the axonal transport is affected, a positive effect of Epo D
treatment has been reported (Barten et al., 2012; Brunden et al., 2010;
Zhang et al., 2012). At the molecular level, Epo D can affect microtubule
dynamics by modifying microtubule stability, thereby regulating micro-
tubule motor efﬁciency, which is known to be involved in the fast axonal
transport ofMn2+. Indeed, themolecularmotors of the kinesin family are
crucially involved in the fast axonal transport of Mn2+; a kinesin light
chain 1 KO mouse exhibited an alteration in neuronal transport, as
assayed byMEMRI (Bearer et al., 2007). EpoD treatmentmight alsomod-
ify microtubule density and reduce axonal dystrophy, as reported in the
tauopathy mouse model (Zhang et al., 2012). These effects will directly
improve fast axonal transport. In our study, Epo D treatment directly
and strongly not only stimulates axonal transport, aswitnessed by the in-
crease in the slope of transported Mn2+ within ipsilateral monosynaptic
tracts, but also seems to improve synaptic transmission because the
speed of Mn2+ transport is also enhanced in polysynaptic contralateral
tracts. Also, the comparison of slope values between WT mice and Epo
D treated KO mice suggests partial recovery which might result from
the axonal ﬁber loss observed in KO mice. The advantage of MEMRI is
to provide an integrated view of all of the effects that occur at amolecular
and a cellular level.
Notably, using MEMRI, another microtubule modulator, NAP
(davunetide), has recently been shown to rescue neuronal transport de-
fects in an amyotrophic lateral sclerosis animalmodel (Jouroukhin et al.,
2013). Interestingly, NAP treatment has been reported to alleviate
MAP6 cognitive disorders (Merenlender-Wagner et al., 2010). One
might speculate that davunetide alleviation of MAP6 KO behavioral dis-
orders can involve the amelioration of the neuronal transport deﬁcit
that we identiﬁed in this study.
Conclusions
In this study, using MEMRI in live animals, we showed that the
MAP6 KO mouse, which is an animal model that is pertinent for the
study of schizophrenia, exhibits an altered neuronal transport capacity,
which is associated with a deﬁcit in some white matter tracts. We
demonstrated that Epo D is able to alleviate the neuronal transport de-
fects that are exhibited byMAP6 KOmice andmost likely contributes to
the reported alleviation of behavioral and cognitive disorders (Andrieux
et al., 2006; Fournet et al., 2012). Thus, complementary to molecular
and cellular studies of neuronal transport, MEMRI is a power tool that
can be used to reveal, in vivo, a neuronal transport deﬁcit and to directly
assay the positive impact of a pharmacological agent on this deﬁcit.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neuroimage.2014.03.071.
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